Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023

-Reported positive results from EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis - -Enrollment on target in EMERALD-2 phase 2b global randomized trial of MORF-057 in UC- ...

Related Keywords

,Praveen Tipirneni ,Chris Erdman ,Morphic Holding Inc ,Securities Exchange ,Exchange Commission ,Globenewswire Inc ,Chief Executive Officer ,Recent Corporate Highlights ,Robarts Histopathology Index ,Mayo Clinic Score ,Simple Endoscopic Score ,Full Year ,Modified Mayo Clinic Score ,Disease Activity Index ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Consolidated Statements ,Consolidated Balance Sheets ,Markets ,